Opioid-Cannabis Co-Users Are Younger, Lower Income, and More Psychologically Distressed

Among 134,402 U.S. adults using prescription opioids and/or cannabis, 15.2% co-used both, and this group was younger, lower-income, and more psychologically distressed than single-substance users.

Kang, Hyojung et al.·Frontiers in public health·2025·Moderate Evidencecross-sectional survey
RTHC-06790Cross Sectional surveyModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cross-sectional survey
Evidence
Moderate Evidence
Sample
N=134,402

What This Study Found

Among adults using prescription opioids and/or cannabis medically, 49.5% used opioids only, 35.3% cannabis only, and 15.2% co-used both. Co-users were younger, had lower income, and experienced more psychological distress. Opioid-only users were older, more female, and in large-metro areas. Cannabis-only users were younger, more male, healthier, and in non-metro areas.

Key Numbers

134,402 adults. Opioid-only: 49.5%. Cannabis-only: 35.3%. Co-use: 15.2%. Depression similarly affected both groups vs co-use (RRR=0.52). Co-users were more likely to be younger, lower income, and psychologically distressed.

How They Did This

Weighted multinomial logistic regression analysis of 2015-2022 NSDUH data for U.S. adults reporting past-year medical use of prescription opioids and/or cannabis.

Why This Research Matters

Understanding who co-uses opioids and cannabis can help clinicians identify patients who may need additional support and inform policy about cannabis as a potential opioid substitute versus complement.

The Bigger Picture

The finding that nearly 1 in 6 medical opioid/cannabis users employ both substances simultaneously complicates the "cannabis as opioid substitute" narrative. For many, cannabis may supplement rather than replace opioid use.

What This Study Doesn't Tell Us

Cross-sectional NSDUH data. Cannot determine if co-use is substitutional, complementary, or incidental. Self-reported medical use may not reflect actual prescriptions. Does not capture dose, frequency, or timing of co-use.

Questions This Raises

  • ?Are co-users using cannabis to reduce opioid doses, or using both at full doses?
  • ?Do co-users have better or worse pain outcomes than single-substance users?

Trust & Context

Key Stat:
15.2% of U.S. adults using prescription opioids and/or cannabis used both substances
Evidence Grade:
Large nationally representative sample with 8 years of data, but cross-sectional design and self-report limitations apply.
Study Age:
2025 publication with 2015-2022 NSDUH data.
Original Title:
Co-use of opioids and cannabis versus single-substance use: a national analysis of US adults.
Published In:
Frontiers in public health, 13, 1623420 (2025)
Database ID:
RTHC-06790

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkTHC

Cite This Study

RTHC-06790·https://rethinkthc.com/research/RTHC-06790

APA

Kang, Hyojung; Tian, Jilin; Milavetz, Gary. (2025). Co-use of opioids and cannabis versus single-substance use: a national analysis of US adults.. Frontiers in public health, 13, 1623420. https://doi.org/10.3389/fpubh.2025.1623420

MLA

Kang, Hyojung, et al. "Co-use of opioids and cannabis versus single-substance use: a national analysis of US adults.." Frontiers in public health, 2025. https://doi.org/10.3389/fpubh.2025.1623420

RethinkTHC

RethinkTHC Research Database. "Co-use of opioids and cannabis versus single-substance use: ..." RTHC-06790. Retrieved from https://rethinkthc.com/research/kang-2025-couse-of-opioids-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.